Kennedy Capital Management’s Corcept Therapeutics CORT Stock Holding History

Kennedy Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.6M	Sell	201,979 -102,636	-34%	-$6.2M	0.31%	101
2026 Q1	$12.3M	Buy	304,615 +94,882	+45%	+$3.55M	0.26%	141
2025 Q4	$7.3M	Buy	209,733 +79,807	+61%	+$6.27M	0.15%	213
2025 Q3	$10.8M	Buy	129,926 +13,913	+12%	+$1.01M	0.24%	145
2025 Q2	$8.52M	Buy	116,013 +30,090	+35%	+$2.18M	0.2%	175
2025 Q1	$9.81M	Buy	85,923 +35,272	+70%	+$2.15M	0.23%	149
2024 Q4	$2.55M	Sell	50,651 -249	-0.5%	-$13K	0.06%	473
2024 Q3	$2.36M	Buy	+50,900	New	+$1.81M	0.05%	484
2024 Q1	–	Sell	-44,929	Closed	-$1.46M	–	736
2023 Q4	$1.46M	Buy	+44,929	New	+$1.23M	0.03%	539

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's CORT Position: Q2 2026 in Review

Kennedy Capital Management reduced its Corcept Therapeutics (CORT) stake by 34% in Q2 2026, selling an estimated $6.2M and leaving 201,979 shares worth $17.6M. The position accounts for 0.31% of the portfolio, ranked #101.

Kennedy Capital Management first reported a position in CORT in Q4 2023 and has held it in 9 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Kennedy Capital Management held 201,979 shares of Corcept Therapeutics worth $17.6M as of Q2 2026.
Kennedy Capital Management sold 102,636 Corcept Therapeutics shares in Q2 2026, an estimated $6.2M.
Corcept Therapeutics made up 0.31% of Kennedy Capital Management's portfolio in Q2 2026, its #101 holding.
Kennedy Capital Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 9 quarters since.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.